AAAAAA

   
Results: 1-8 |
Results: 8
Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
Authors: Rudin, CM Holmlund, J Fleming, GF Mani, S Stadler, WM Schumm, P Monia, BP Johnston, JF Geary, R Yu, RZ Kwoh, TJ Dorr, FA Ratain, MJ
Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220
Clinical safety of phosphorothioate oligodeoxynucleotides
Authors: Dorr, FA Glover, JG Kwoh, TJ
Citation: Fa. Dorr et al., Clinical safety of phosphorothioate oligodeoxynucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 269-290
Antisense approaches for the treatment of cancer
Authors: Monia, BP Holmlund, J Dorr, FA
Citation: Bp. Monia et al., Antisense approaches for the treatment of cancer, CANCER INV, 18(7), 2000, pp. 635-650
Antisense oligonucleotides in the treatment of cancer
Authors: Dorr, FA
Citation: Fa. Dorr, Antisense oligonucleotides in the treatment of cancer, ANTISENSE N, 9(4), 1999, pp. 391-396
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)
Authors: O'Dwyer, PJ Stevenson, JP Gallagher, M Cassella, A Vasilevskaya, I Monia, BP Holmlund, J Dorr, FA Yao, KS
Citation: Pj. O'Dwyer et al., c-raf-1 depletion and tumor responses in patients treated with the c-raf-1antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A), CLIN CANC R, 5(12), 1999, pp. 3977-3982
Phase I clinical pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
Authors: Stevenson, JP Yao, KS Gallagher, M Friedland, D Mitchell, EP Cassella, A Monia, B Kwoh, TJ Yu, R Holmlund, J Dorr, FA O'Dwyer, PJ
Citation: Jp. Stevenson et al., Phase I clinical pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A), J CL ONCOL, 17(7), 1999, pp. 2227-2236
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
Authors: Rinaldi, DA Kuhn, JG Burris, HA Dorr, FA Rodriguez, G Eckhardt, SG Jones, S Woodworth, JR Baker, S Langley, C Mascorro, D Abrahams, T Von Hoff, DD
Citation: Da. Rinaldi et al., A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation, CANC CHEMOT, 44(5), 1999, pp. 372-380
Tamoxifen and fenretinide in women with metastatic breast cancer
Authors: Zujewski, J Pai, L Wakefield, L Giusti, R Dorr, FA Flanders, C Caruso, R Kaiser, M Goodman, L Merino, M Gossard, M Noone, MA Denicoff, A Venzon, D Cowan, KH O'Shaughnessy, JA
Citation: J. Zujewski et al., Tamoxifen and fenretinide in women with metastatic breast cancer, BREAST CANC, 57(3), 1999, pp. 277-283
Risultati: 1-8 |